Nephronophthisis 13 (NPHP13) Cell Models for Research

Nephronophthisis 13 (NPHP13) is a rare autosomal recessive cystic kidney disease, part of the nephronophthisis (NPHP) group. It is caused by mutations in the WDR19 gene (also known as NPHP13). The exact prevalence is unknown, but NPHP collectively affects approximately 1 in 50,000 to 1 in 900,000 individuals worldwide (WHO rare disease data). NPHP13 typically presents in childhood or adolescence with polyuria, polydipsia, and progressive renal failure, leading to end-stage renal disease (ESRD) by the second or third decade. There is no cure, and current treatments are supportive, including dialysis and transplantation. The disease burden is significant due to early onset and lifelong impact.

NPHP13 is an ideal model for studying ciliary function and renal fibrosis. The WDR19 gene encodes a component of the intraflagellar transport (IFT) complex A, essential for cilia assembly and function. Mutations disrupt ciliary signaling, leading to renal cystic disease. Research models, including gene-edited cell lines, are crucial for understanding the molecular mechanisms and developing targeted therapies. Public datasets, such as those in ClinVar and the Human Gene Mutation Database, provide mutation information, but functional studies are limited, highlighting the need for reliable in vitro models.

NPHP13 is not a cancer, but a ciliopathy. However, the pathways involved are relevant to cell proliferation and differentiation. Key pathways include:

• • Hedgehog (Hh) signaling: Cilia are essential for Hh signal transduction. Defects in IFT-A impair Hh signaling, leading to abnormal cell proliferation.
• • Wnt signaling: Cilia modulate canonical and non-canonical Wnt pathways. Disruption can cause planar cell polarity defects and cyst formation.
• • mTOR signaling: Ciliary dysfunction can lead to dysregulated mTOR activity, contributing to cyst growth.
• • DNA damage response: Some ciliary proteins are involved in DNA repair; defects may increase genomic instability.

Data from ClinVar and literature.

The primary deregulated network is the ciliary signaling network. Key nodes include:

• • IFT-A complex: WDR19 is a component; mutations disrupt retrograde transport.
• • Hedgehog pathway: GLI transcription factors are affected.
• • Wnt pathway: Dishevelled and β-catenin are misregulated.
• • mTORC1: Hyperactivation is observed in cystic kidneys.
• • Autophagy: Ciliary dysfunction impairs autophagic flux.

Organoids derived from patient iPSCs can recapitulate kidney development and cystic phenotypes, providing a more physiologically relevant model.

• • Genetically engineered mouse models (GEMMs): Wdr19 knockout mice exhibit renal cysts and ciliary defects.
• • Zebrafish models: wdr19 morpholino knockdown causes cystic kidneys.
• • Induced models: Chemical induction of ciliary dysfunction in mice.
• • Patient-derived xenografts (PDX) are not applicable for non-cancer diseases.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with specific WDR19 mutations. For example:

• • WDR19 knockout cell lines: Complete loss of function, mimicking null mutations.
• • WDR19 point mutation knock-in lines: Introduction of specific missense mutations (e.g., p.Arg1234Gln) to study genotype-phenotype correlations.
• • Reporter lines: GFP-tagged WDR19 to track protein localization.

These models are commercially available from various sources, ensuring sequence verification and quality control. They are essential for drug screening and functional studies.

Gene-edited cell lines allow validation of WDR19 mutations' pathogenicity. For example, knocking out WDR19 in renal epithelial cells leads to ciliary shortening and abnormal signaling, confirming its role. Knock-in of patient-specific mutations can reveal allele-specific effects. These models are used in CRISPR screens to identify genetic modifiers.

Isogenic pairs (wild-type vs. WDR19 knockout) are used to screen for compounds that rescue ciliary defects or reduce cyst formation. High-throughput screening can identify drugs that modulate mTOR or Hedgehog pathways. Resistance models can be developed to test long-term efficacy.

CRISPR-based synthetic lethality screens in WDR19-deficient cells can identify vulnerabilities that may serve as therapeutic targets. Secreted proteins from mutant cells can be analyzed for potential biomarkers of disease progression.